Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.34 |
| ▸ | MGAM | O43451 | 2/20 | 0.34 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | SI | P14410 | 2/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1312086 | 0.80 | SLC9A1 (0.55) | GRM2PTK2SLC9A1RAB9A | |
| SCHEMBL24483865 | 0.72 | HCAR3 (0.46) | HCAR3SLC9A1MGAMAMY1AGAA | |
| SCHEMBL23119707 | 0.71 | HCAR3 (0.58) | GRM2HCAR3SLC9A1MGAMAMY1A | |
| SCHEMBL23119752 | 0.69 | HCAR3 (0.63) | HCAR3SLC9A1RAB9APOLB | |
| SCHEMBL25339436 | 0.68 | PTK2 (0.50) | GRM2PTK2HCAR3SLC9A1MGAM | |
| SCHEMBL26449157 | 0.66 | AR (0.49) | HCAR3SLC9A1MGAMAMY1AGAA | |
| SCHEMBL1312576 | 0.66 | TDO2 (0.53) | HCAR3MGAMAMY1AGAASI | |
| SCHEMBL251664 | 0.66 | PTK2 (0.40) | GRM2PTK2SLC9A1MGAMAMY1A | |
| SCHEMBL12100525 | 0.66 | HCAR3 (0.54) | HCAR3SLC9A1RAB9APOLBTDO2 | |
| SCHEMBL9636128 | 0.66 | PABPC1 (0.36) | HCAR3MGAMAMY1AGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2387568-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NeuroSearch A/S (DK) | 2011-11-23 | — | — | EP | claimed |
| US-20110275684-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2011-11-10 | — | — | US | claimed |
| US-8040036-B2 | Organic light emitting device and method for manufacturing the same | LG CHEM, LTD. (KR) | 2011-10-18 | — | — | US | claimed |
| WO-2010081898-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-07-22 | — | — | WO | claimed |
| EP-2387568-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NeuroSearch A/S (DK) | 2011-11-23 | — | — | EP | disclosed |
| US-20110275684-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2011-11-10 | — | — | US | disclosed |
| US-8040036-B2 | Organic light emitting device and method for manufacturing the same | LG CHEM, LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| WO-2010081898-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275684-A1 | NOVEL BENZOTRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | GABBR1, ABAT, GABBR2 | GRM2 118/4885PTK2 4697/4885HCAR3 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.